Inhibikase Therapeutics (IKT) Develops New Formulation of risvodetinib Aug 24, 2023 08:32AM
Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib Aug 24, 2023 08:30AM
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders Aug 22, 2023 08:05AM
Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib Aug 21, 2023 08:30AM
Inhibikase Therapeutics (IKT) Completes 501 Bioequivalence Study of IkT-001Pro Aug 17, 2023 08:32AM
View Older Stories

Aug 17, 2023 08:30AM Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
Aug 14, 2023 04:20PM Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Aug 7, 2023 08:05AM Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
Jul 17, 2023 04:06PM Inhibikase Therapeutics (IKT) Regains Compliance with Nasdaq Listing Requirements
Jul 17, 2023 04:05PM Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
Jun 29, 2023 09:29AM Inhibikase Therapeutics (IKT) Announces a 1-for-6 Reverse Stock Split
Jun 29, 2023 09:29AM Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
Jun 22, 2023 08:06AM Inhibikase Therapeutics (IKT) Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
Jun 22, 2023 08:05AM Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
Jun 21, 2023 08:05AM Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
May 30, 2023 08:05AM Inhibikase Therapeutics to Present at the LD Micro Invitational XIII
May 16, 2023 07:45AM Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
May 15, 2023 08:30AM Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 8, 2023 08:05AM Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
May 4, 2023 08:05AM Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
Apr 26, 2023 08:04AM Inhibikase Therapeutics (IKT) Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial
Apr 26, 2023 08:00AM Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
Apr 21, 2023 08:30AM Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
Mar 31, 2023 08:22AM Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity
Mar 23, 2023 05:15PM Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
Mar 21, 2023 08:00AM Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders
Mar 16, 2023 08:30AM Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023
Mar 15, 2023 08:35AM Inhibikase Therapeutics (IKT) Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro
Mar 15, 2023 08:35AM Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro
Mar 8, 2023 08:35AM Inhibikase Therapeutics (IKT) Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
Mar 8, 2023 08:30AM Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
Feb 15, 2023 04:05PM Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
Jan 27, 2023 04:05PM Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules
Jan 25, 2023 01:04PM Inhibikase Therapeutics (IKT) Announces $10M Direct Offering and Private Placement at $0.86/sh
Jan 25, 2023 01:00PM Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules
Jan 25, 2023 08:36AM Inhibikase Therapeutics (IKT) Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target
Jan 25, 2023 08:35AM Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders
Jan 25, 2023 08:06AM Inhibikase Therapeutics (IKT) Announces FDA has Lifted the Full Clinical Hold on IkT-148009
Jan 25, 2023 08:05AM Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
Dec 12, 2022 04:05PM Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro
Dec 7, 2022 04:06PM Inhibikase Therapeutics (IKT) Provides Update to FDA Clinical Hold of IkT-148009 Programs
Dec 7, 2022 04:05PM Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs
Nov 22, 2022 08:00AM Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
Nov 14, 2022 05:45PM Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
Nov 8, 2022 08:00AM Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
Nov 7, 2022 08:01AM Inhibikase Therapeutics (IKT) Announces FDA Clinical Hold on IkT-148009 Programs
Nov 7, 2022 08:00AM Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
Oct 12, 2022 08:00AM Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference
Sep 21, 2022 04:05PM Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference
Sep 15, 2022 08:00AM Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress
Sep 8, 2022 08:30AM Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
Sep 1, 2022 04:05PM Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors
Aug 26, 2022 08:00AM Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Aug 23, 2022 08:00AM Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
Aug 12, 2022 04:55PM Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
View Older Stories